214 related articles for article (PubMed ID: 25794491)
1. A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Holgersson G; Bergström S; Harmenberg J; Ringbom M; Klockare M; Jerling M; Ekman S; Lundström KL; Koyi H; Brandén E; Larsson O; Bergqvist M
Med Oncol; 2015 Apr; 32(4):129. PubMed ID: 25794491
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
[TBL] [Abstract][Full Text] [Related]
3. A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.
Ekman S; Harmenberg J; Frödin JE; Bergström S; Wassberg C; Eksborg S; Larsson O; Axelson M; Jerling M; Abrahmsen L; Hedlund Å; Alvfors C; Ståhl B; Bergqvist M
Acta Oncol; 2016; 55(2):140-8. PubMed ID: 26161618
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients.
Tournoux-Facon C; Senellart H; Lemarie E; Tourani JM; Favrel S; Pouget JC; Pinel MC; Bennouna J
J Thorac Oncol; 2011 Jul; 6(7):1247-53. PubMed ID: 21610520
[TBL] [Abstract][Full Text] [Related]
5. Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.
Karampeazis A; Vamvakas L; Kentepozidis N; Polyzos A; Chandrinos V; Rigas G; Christofyllakis C; Kotsakis A; Hatzidaki D; Pallis AG; Georgoulias V
Clin Lung Cancer; 2016 Nov; 17(6):543-549. PubMed ID: 27397849
[TBL] [Abstract][Full Text] [Related]
6. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
Leggas M; Kuo KL; Robert F; Cloud G; deShazo M; Zhang R; Li M; Wang H; Davidson S; Rinehart J
Cancer Chemother Pharmacol; 2009 Mar; 63(4):731-43. PubMed ID: 18500521
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
Usami N; Yokoi K; Hasegawa Y; Taniguchi H; Shindo J; Yamamoto M; Suzuki R; Imaizumi K; Kondo M; Shimokata K;
Int J Clin Oncol; 2010 Dec; 15(6):583-7. PubMed ID: 20714770
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Laskin JJ; Nicholas G; Lee C; Gitlitz B; Vincent M; Cormier Y; Stephenson J; Ung Y; Sanborn R; Pressnail B; Nugent F; Nemunaitis J; Gleave ME; Murray N; Hao D
J Thorac Oncol; 2012 Mar; 7(3):579-86. PubMed ID: 22198426
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.
Kortsik C; Albrecht P; Elmer A
Lung Cancer; 2003 Apr; 40(1):85-90. PubMed ID: 12660012
[TBL] [Abstract][Full Text] [Related]
10. Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
Bergqvist M; Holgersson G; Bondarenko I; Grechanaya E; Maximovich A; Andor G; Klockare M; Thureson M; Jerling M; Harmenberg J
Acta Oncol; 2017 Mar; 56(3):441-447. PubMed ID: 27882820
[TBL] [Abstract][Full Text] [Related]
11. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C
Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A
Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971
[TBL] [Abstract][Full Text] [Related]
14. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer.
Choy H; Jain AK; Moughan J; Curran W; Whipple G; Demas WF; Ettinger DS
J Thorac Oncol; 2009 Jan; 4(1):80-6. PubMed ID: 19096311
[TBL] [Abstract][Full Text] [Related]
15. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
16. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Edelman MJ; Belani CP; Socinski MA; Ansari RH; Obasaju CK; Chen R; Monberg MJ; Treat J;
J Thorac Oncol; 2010 Jan; 5(1):110-6. PubMed ID: 20035187
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
[TBL] [Abstract][Full Text] [Related]
19. Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Schallier D; Bral S; Ilsen B; Neyns B; Fontaine C; Decoster L; De Mey J; Meysman M; De Grève J
J Thorac Oncol; 2009 Jun; 4(6):728-35. PubMed ID: 19404217
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Okamoto I; Yoshioka H; Takeda K; Satouchi M; Yamamoto N; Seto T; Kasahara K; Miyazaki M; Kitamura R; Ohyama A; Hokoda N; Nakayama H; Yoshihara E; Nakagawa K
J Thorac Oncol; 2012 Feb; 7(2):427-33. PubMed ID: 22071785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
